Cargando…
ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines
BACKGROUND: Although 40–50% of non-small cell lung cancer (NSCLC) tumors respond to cisplatin chemotherapy, there currently is no way to prospectively identify potential responders. The purpose of this study was to determine whether transcript abundance (TA) levels of twelve selected DNA repair or m...
Autores principales: | Weaver, David A, Crawford, Erin L, Warner, Kristy A, Elkhairi, Fadel, Khuder, Sadik A, Willey, James C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156938/ https://www.ncbi.nlm.nih.gov/pubmed/15882455 http://dx.doi.org/10.1186/1476-4598-4-18 |
Ejemplares similares
-
ERCC1 and XRCC1 but not XPA single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma
por: Chen, Liang, et al.
Publicado: (2016) -
Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
por: Mendoza, J, et al.
Publicado: (2013) -
Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction
por: Barakat, Khaled H., et al.
Publicado: (2012) -
Pterygium and genetic polymorphisms of the DNA repair enzymes XRCC1, XPA, and XPD
por: Chiang, Chun-Chi, et al.
Publicado: (2010) -
ERCC1–XPF targeting to psoralen–DNA crosslinks depends on XPA and FANCD2
por: Sabatella, Mariangela, et al.
Publicado: (2019)